DP13 - A Phase II Study in Patients With Primary Aldosteronism
NCT ID: NCT04007406
Last Updated: 2024-11-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
35 participants
INTERVENTIONAL
2019-11-21
2022-05-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency
NCT00004313
An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
NCT01739582
A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male Subject
NCT03196557
Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men
NCT01382069
Androxal in Male Infertility
NCT02160704
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
4 mg DP13 daily
DP13 for 8 weeks
dexfadrostat phosphate
DP13 systemic administration
8 mg DP13 daily
DP13 for 8 weeks
dexfadrostat phosphate
DP13 systemic administration
12 mg DP13 daily
DP13 for 8 weeks
dexfadrostat phosphate
DP13 systemic administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dexfadrostat phosphate
DP13 systemic administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* hyperkalemia
* prolonged QT intervals
* refusal of special contraception measures
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Damian Pharma AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paolo Mulatero, Prof
Role: PRINCIPAL_INVESTIGATOR
University of Torino, Torino, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedale Molinette
Torino, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DP13C201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.